Independent peptide intelligence · 2026
The breadth of a catalog.
The depth of a monograph.
190+ monographs on peptides, SARMs, bioregulators and small molecules — each graded on four separate dimensions: what regulators have decided, the state of human evidence, molecular type, and public interest. Never blended into one score.
Popular now
Interest is a signal. Evidence is the filter.
The three most-visited monographs this month — with their evidence context up front.
BPC-157
High interestBPC-157 is the archetype of the gap between preclinical promise and clinical reality. The animal literature is broad — tendon, muscle, ligament, gut and nerve injury models in rodents, almost entirely from a single research lineage — but no registered, completed, peer-reviewed controlled human trial exists at all.
Biggest unknown: All human pharmacokinetics, safety and efficacy
Read monographRetatrutide
High interestRetatrutide is the high point of current metabolic science: a phase II trial showed ~24% average body weight loss at 48 weeks — the largest effect ever recorded in the peptide class. The glucagon component also brings lipid benefits.
Biggest unknown: Full phase III efficacy and safety
Read monographTesamorelin
High interestTesamorelin is one of the few peptides on this list that is a genuine, regulator-approved drug: FDA approved it in 2010 to reduce visceral abdominal fat in HIV-associated lipodystrophy. In large RCTs it reduced visceral adipose tissue ~15–18% with an acceptable profile; IGF-1 rises were consistent.
Biggest unknown: Long-term cardiovascular safety
Read monographResearch Desk
What the trial actually showed.
Short reads on human trials, evidence audits and regulatory decisions — tied to the monographs, with a verdict at the end.
HUMAN TRIAL · September 19, 2026
Retatrutide's phase 2 numbers still look unreal. They aren't.
The triple agonist produced a 24% mean weight loss in a 48-week trial — a result no approved drug has matched since. What the data actually says, and what it doesn't.
WATCH
MARKET WATCH · September 12, 2026
CagriSema vs retatrutide: the incretin arms race, scored on data
Novo Nordisk filed first. Eli Lilly's molecule is stronger. A head-to-head read of REDEFINE 1, REDEFINE 4 and TRIUMPH-4 — without the marketing.
WATCH
EVIDENCE AUDIT · September 5, 2026
BPC-157 has 200+ animal studies and one core problem
The most popular research peptide in the world has never completed a single registered human trial. Why that gap matters more than any individual rodent result.
OVERHYPED
How we classify
Four dimensions. Never blended into one score.
Regulatory status
What regulators have actually decided — nowhere blended with evidence.
Evidence context
The state of research, from unknown to robust human RCTs.
Molecular type
Taxonomy — peptide, analog, fragment — never a quality signal.
Public interest
How much attention an entry is getting. Attention is not evidence.
A high-interest compound can have weak evidence. An approved drug can be boring. We keep the signals separate so you can think clearly.
Browse by goal
Start from what you are trying to understand.
Series
Guided reading series
Curated paths through the codex: sequences of monographs meant to be read one after another, with an editorial intro. Not courses — the same codex, just organized.
Start the seriesTools
Tools
Interactive tools that aid understanding — they calculate and visualize, but they do not recommend.
Open toolBuilt like a sourcebook. Updated like a newsroom.
Answer-first monographs
Every entry opens with the plain-language verdict, then the detail — mechanism, evidence, risks, unknowns.
Official vs community — always separated
Regulator-approved labeling and trial designs never share a lane with self-reports.
Last-verified dates on every entry
A verification stamp on every entry shows exactly when its claims were last checked.
Independent knowledge base · No affiliate links · No sales
Read our editorial standards